ANNX (Annexon) Earnings Yield (Joel Greenblatt) % : -41.67% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Annexon Earnings Yield (Joel Greenblatt) %?

Annexon's Enterprise Value for the quarter that ended in Sep. 2024 was $315.29 Mil. Annexon's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-131.60 Mil. Annexon's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2024 was -41.67%.

The historical rank and industry rank for Annexon's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

ANNX' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -70714542.42 Med: 0 Max: 705709.29
Current: -96.15

During the past 6 years, the highest Earnings Yield (Joel Greenblatt) of Annexon was 705709.29%. The lowest was -70714542.42%. And the median was 0.00%.

ANNX's Earnings Yield (Joel Greenblatt) % is ranked worse than
84.64% of 1354 companies
in the Biotechnology industry
Industry Median: -13.655 vs ANNX: -96.15

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Annexon's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

Annexon Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Annexon's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annexon Earnings Yield (Joel Greenblatt) % Chart

Annexon Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings Yield (Joel Greenblatt) %

Get a 7-Day Free Trial

-10.52

-55.56

-400.00

-112.36

Annexon Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Earnings Yield (Joel Greenblatt) %	Get a 7-Day Free Trial															2,000.00	-112.36	-31.65	-70.92	-41.67

Competitive Comparison of Annexon's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Annexon's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annexon's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annexon's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Annexon's Earnings Yield (Joel Greenblatt) % falls into.

Annexon Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Annexons Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)	=	EBIT	/	Enterprise Value
	=	-143.723	/	127.434714
	=	-112.78 %

Annexon's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-131.60 Mil.

Annexon (NAS:ANNX) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.

Be Aware

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.

Annexon Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Annexon's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.

Annexon Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annexon Inc (NAS:ANNX) » Definitions » Earnings Yield (Joel Greenblatt) %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1400 Sierra Point Parkway, Suite 200, Building C, Brisbane, CA, USA, 94005

Website

https://www.annexonbio.com

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Executives

William H. Carson	director	C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 1520, NEW YORK NY 10016
Ted Yednock	officer: EVP & Chief Innovation Officer	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Jennifer Lew	officer: EVP & Chief Financial Officer	2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Michael Overdorf	officer: EVP & Chief Business Officer	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Douglas Love	director, officer: President & CEO	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Muneer A Satter	director	C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Jamie Dananberg	officer: Chief Medical Officer	3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Bain Capital Life Sciences Fund, L.p.	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Dean Richard Artis	officer: EVP & Chief Scientific Officer	C/O ANNEXON, INC., 1400 SIERRA PT PKWY, BLDG C, 2ND FLOOR, BRISBANE CA 94005
Bettina M. Cockroft	director	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Larry Mattheakis	officer: Chief Scientific Officer	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
William D. Waddill	director	C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Sanjay Keswani	officer: EVP & Chief Medical Officer	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Clarus Lifesciences Iii, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017